Orlando; Elena

Patent Applications and Registrations

Patent applications and USPTO patent grants for Orlando; Elena.The latest application filed is for "cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell".

Company Profile

4.3.10

Orlando; Elena - Somerville MA
Orlando; Elena - Cambridge MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Cd20 Therapies, Cd22 Therapies, And Combination Therapies With A Cd19 Chimeric Antigen Receptor (car)- Expressing Cell App 20220195010 - Bitter; Hans ; et al.	2022-06-23
Biomarkers For Evaluating Car-t Cells To Predict Clinical Outcome App 20210396739 - Pruteanu-Malinici; Iulian ; et al.	2021-12-23
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Grant 11,149,076 - Bitter , et al. October 19, 2	2021-10-19
Combination Therapy With Chimeric Antigen Receptor (car) Therapies App 20210213063 - Isaacs; Randi ; et al.	2021-07-15
Biomarkers Predictive Of Therapeutic Responsiveness To Chimeric Antigen Receptor Therapy And Uses Thereof App 20210172020 - Bedoya; Felipe ; et al.	2021-06-10
Methods Of Making Chimeric Antigen Receptor-expressing Cells App 20200370012 - Fraietta; Joseph A. ; et al.	2020-11-26
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof Grant 10,774,388 - Bedoya , et al. Sept	2020-09-15
Cd20 Therapies, Cd22 Therapies, And Combination Therapies With A Cd19 Chimeric Antigen Receptor (car)- Expressing Cell App 20190292238 - Bitter; Hans ; et al.	2019-09-26
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Grant 10,253,086 - Bitter , et al.	2019-04-09
Biomarkers Predictive Of Therapeutic Responsiveness To Chimeric Antigen Receptor Therapy And Uses Thereof App 20170306416 - Bedoya; Felipe ; et al.	2017-10-26
Cd20 Therapies, Cd22 Therapies, And Combination Therapies With A Cd19 Chimeric Antigen Receptor (car)- Expressing Cell App 20160362472 - Bitter; Hans ; et al.	2016-12-15

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.